-
Lepanto Consolidated Mining (LC) Likely To Hit PHP 1.00
Wednesday, June 1, 2011 - 10:40pm | 501Hot shot Lepanto Consolidated Mining Corporation or LC in the Philippine Stock Exchange looks like it's going to hit the PHP 1.00 mark soon. LC has a stronghold for the best performing stock of the year with a year-to-date return of more than 97% so far. And based on its chart,...
-
Second Wave of Russell ETFs Comes Ashore
Wednesday, June 1, 2011 - 6:29pm | 1730Boom! Russell Investments jumped from sponsoring just one ETF to 17 in a span of less than 10 days. The firm introduced a 10-fund suite of Russell Factor ETFs last Friday (5/27/11). The second wave of new products comes quick on the heels of the Russell Investment Discipline Index ETFs rollout....
-
Teva Announces Launch of Generic Aricept® Tablets in the United States
Wednesday, June 1, 2011 - 2:52pm | 76Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this...
-
Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer
Wednesday, June 1, 2011 - 12:13pm | 225Hapoalim Securities is terminating coverage of Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), Pfizer (NYSE: PFE), Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS), Amarin (NASDAQ: AMRN), Amylin (NASDAQ: AMLN), Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL),...
-
Hapoalim Cutting Ocverage On Multitude Of Names
Wednesday, June 1, 2011 - 11:48am | 237Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure. The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ:...
-
Citi Sets Pfizer Price Target At $23
Wednesday, June 1, 2011 - 7:50am | 151According to Citi, Pfizer (NYSE: PFE) price target is $23. Citi said that it arrives at its $23 target price for Pfizer based on a relative P/E compared to the US Drug peer group. “We assume PFE trades at ~10x our 2012E EPS of $2.29, or roughly in-line with its peers. Although PFE's growth...
-
TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from China's SFDA
Wednesday, June 1, 2011 - 7:33am | 35Tianyin Pharmaceutical Co., Inc. (NYSE: TPI) today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.
-
TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from China's SFDA
Wednesday, June 1, 2011 - 7:33am | 35Tianyin Pharmaceutical Co., Inc. (NYSE: TPI) today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.
-
Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE
Wednesday, June 1, 2011 - 1:12am | 141Below are the top large-cap drug manufacturers-major stocks on the NYSE and the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Eli Lilly and Company (NYSE: LLY) is 39.98%. LLY's operating margin for the same period is 29.08%. The trailing-twelve-month return on...
-
Mad Money Lightning Round: Cramer Dislikes Staples
Wednesday, June 1, 2011 - 1:08am | 231On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Staples (NASDAQ: SPLS) had a “terrible quarter.” He doesn't like the stock. Cramer said that Tesla Motors (NASDAQ: TSLA) is “too speculative.” He added, “I'd rather play it with NRG Energy (NYSE: NRG) or Eaton (NYSE: ETN) or even...
-
Jefferies Supports Premium Pricing on Dificid by Optimer Pharmacy (OPTR)
Tuesday, May 31, 2011 - 10:31pm | 244Earlier today, analysts from Jefferies published a company note on the launch of a new drug Dificid by Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR). The analysts maintain the Buy rating and a price target of $17. Following the FDA approval on May 27th, OPTR will price Dificid at $2,800 for a 10-...
-
Jefferies Supports Premium Pricing on Dificid by Optimer Pharmacy (OPTR)
Tuesday, May 31, 2011 - 10:31pm | 244Earlier today, analysts from Jefferies published a company note on the launch of a new drug Dificid by Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR). The analysts maintain the Buy rating and a price target of $17. Following the FDA approval on May 27th, OPTR will price Dificid at $2,800 for a 10-...
-
Headline Away from Adding Volatility 05-31-2011
Tuesday, May 31, 2011 - 6:39pm | 911Cusick's Corner A few weeks ago I wrote that I had never seen a market top when retail sentiment shifted to the sidelines so quickly. But the skeptics are gaining some decent bullets, the data stinks. This has investors scratching their heads, watching this market run. But traders are just waiting...
-
Dollar Weak, Market Pops 05-31-2011
Tuesday, May 31, 2011 - 2:53pm | 1035Cusick's Corner If you are trading headlines then this is your market. If you are trading data, well this is a frustrating time. The market has rallied with the weakness in the buck which has been attributed to the rhetoric that the Germans potentially might soften the Greek austerity plan. While...
-
Stocks Get Boost From Greece Bailout Talk
Tuesday, May 31, 2011 - 2:15pm | 124(TheStreet) -- Stocks were higher Tuesday on hopes that European officials may approve a new aid package for Greece, but gains were tempered by disappointing domestic economic data. The Dow Jones Industrial Average was up by 53 points, or 0.4%, at 12,494 after surging to as high as 12,574 early in...